Application of Belimumab in childhood-onset systemic lupus erythematosus
10.3760/cma.j.cn101070-20200925-01561
- VernacularTitle:贝利木单抗在儿童系统性红斑狼疮中的应用
- Author:
Zhaoling WANG
1
;
Meiping LU
Author Information
1. 浙江大学医学院附属儿童医院风湿免疫过敏科，国家儿童健康与疾病临床医学研究中心，杭州 310052
- Keywords:
Child;
Systemic lupus erythematosus;
Treatment;
Biologics;
Belimumab
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(5):398-400
- CountryChina
- Language:Chinese
-
Abstract:
There is no specific medicine for systemic lupus erythematosus (SLE). Compared with adult-onset SLE, childhood-onset SLE is characterized by severe condition, rapid changes, and poor prognosis.Glucocorticoids are the first-line drugs for SLE.However, some are still difficult to be controlled using the conventional drugs like glucocorticoids and immunosuppressive agents.Belimumab is the only biological agent approved for the use in both adults and childhood-onset SLE, although its application in children lacks clinical experiences.This study aims to review the application of Belimumab in childhood-onset SLE.
